Pluristem Therapeutics Inc. and American Stock Transfer & Trust Company, LLC, as Warrant AgentWarrant Agent Agreement • April 5th, 2019 • Pluristem Therapeutics Inc • Biological products, (no disgnostic substances) • New York
Contract Type FiledApril 5th, 2019 Company Industry JurisdictionWARRANT AGENT AGREEMENT, dated as of April __, 2019 (“Agreement”), between Pluristem Therapeutics Inc., a Nevada corporation (the “Company”), and American Stock Transfer & Trust Company, LLC, a New York limited liability trust company (the “Warrant Agent”).
SUBSCRIPTION AGREEMENTSubscription Agreement • April 5th, 2019 • Pluristem Therapeutics Inc • Biological products, (no disgnostic substances)
Contract Type FiledApril 5th, 2019 Company IndustryThis Subscription Agreement (this “Subscription”) is dated as of April 4, 2019, by and between Pluristem Therapeutics Inc., a Nevada corporation (the “Company”), and the investor identified on the signature page hereto (including its successors and assigns, the “Investor”).
27,142,858 Shares and Warrants to purchase 27,142,858 Shares UNDERWRITING AGREEMENTWarrant Agent Agreement • April 5th, 2019 • Pluristem Therapeutics Inc • Biological products, (no disgnostic substances) • New York
Contract Type FiledApril 5th, 2019 Company Industry JurisdictionPLURISTEM THERAPEUTICS INC., a Nevada corporation (the “Company”), proposes to issue and sell to Ladenburg Thalmann & Co. Inc. (the “Representative”) and the other underwriters listed on Schedule I hereto (collectively, with the Representative, the “Underwriters”), pursuant to and in accordance with the terms and conditions of this underwriting agreement (the “Agreement”) in a public offering (the “Offering”), an aggregate of 27,142,858 shares (the “Shares”) of its common stock, par value $0.00001 per share (the “Common Stock”), and warrants (each whole warrant, a “Warrant”) to purchase up to an aggregate of 27,142,858 shares of Common Stock. The Shares to be sold by the Company are called the “Firm Shares.” The Firm Shares and the Warrants will be sold as units (the “Units”), with each Unit consisting of one Share and a Warrant to purchase one Share. In addition, the Company has granted to the Underwriters an option to purchase up to an additional 1,428,571 Shares as provided in Secti